The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
WJOG6110B (ELTOP): Randomized phase II trial comparing trastuzumab plus capecitabine (HX) and lapatinib plus capecitabine (LX) in HER2-positive metastatic breast cancer patients previously treated with trastuzumab and taxanes.
Toshimi Takano
No relevant relationships to disclose
Hideharu Kimura
No relevant relationships to disclose
Kazuto Nishio
No relevant relationships to disclose
Takeharu Yamanaka
No relevant relationships to disclose
Yoshinori Ito
No relevant relationships to disclose
Junya Fukuoka
No relevant relationships to disclose
Junji Tsurutani
No relevant relationships to disclose
Yasushi Shigeoka
No relevant relationships to disclose
Masahiro Uehara
No relevant relationships to disclose
Kazuhiko Sato
No relevant relationships to disclose
Shinichiro Nakamura
No relevant relationships to disclose
Yoichi Nakanishi
No relevant relationships to disclose
Toshiaki Saeki
No relevant relationships to disclose